All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

News

Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

April 29, 2010

FDA Issues Genzyme Draft Consent Decree for Massachusetts Manufacturing Facility

Author(s):

Patricia Van Arnum

Genzyme provided an update on its manufacturing operations following the issuance of a draft consent decree by FDA regarding the company's Allston Landing, Massachusetts, manufacturing plant.

 The biopharmaceutical company Genzyme (Cambridge, MA) provided an update on its manufacturing operations following the issuance of a draft consent decree by the US Food and Drug Administration regarding the company’s Allston Landing, Massachusetts, manufacturing plant. FDA issued a warning letter to Genzyme in February 2009 following inspection of the facility in Allston Landing for good manufacturing practice (GMP) violations in the manufacture of drug products, bulk drug substances, and drug components for Fabrazyme (agalsidase beta), Cerezyme (imiglucerase for injection), and Myozyme (alglucosidase alfa).

Genzyme reported in its first-quarter 2010 earnings reportthat the consent-decree draft provides for an upfront disgorgement of past profits of $175 million, an expense that Genzyme booked in the first quarter. Genzyme reported a net loss of $114.9 million in the first quarter of 2010 compared with net income of $195.5 million in the year-ago period, based on results calculated under generally accepted accounting principles (GAAP). The GAAP results reflect the impact of the anticipated $175-million expense associated with the consent decree for the company’s Allston manufacturing facility. If the Allston fill–finish facility is still operating after deadlines for domestic and exported products, the draft consent decree provides for disgorgement of 18.5% of revenues from sales of products manufactured and distributed from Allston after those deadlines.

Genzyme and the FDA are discussing appropriate deadlines for moving fill–finish operations and the details of the disgorgement provisions, according to the company’s earnings statement. If fill–finish operations are moved from Allston, but certain remediation actions relating to overall GMP compliance are not met by deadlines during coming years in a remediation plan to be approved by FDA, the draft provides for a payment of $15,000 per day per violation until the compliance milestones are met. Genzyme is negotiating with FDA on the terms of the consent decree and expects that the negotiations will be completed during the second quarter. After finalization of the consent decree, Genzyme will provide an update, including a revised 2010 financial guidance.

Product supply update
Genzyme also provided an update of its product supply from the Allston facility. The company said that it met its goal of building a small inventory buffer for Cerezyme during the first quarter. The current shipping allocation of 50% of demand will be extended because of an interruption in operations at the company’s Allston facility late in the first quarter. The company said that the interruption resulted from an unexpected city electrical power failure that compounded issues with the plant’s water system, which have been corrected. The facility is fully operational, according to the Genzyme.

Genzyme estimates that it will need to continue the 50% shipping allocation for two to three months. The company will provide a more precise supply update within a month, after determining whether Cerezyme material that was unfinished when the interruption occurred can be finished, the impact of the pending consent decree on product- release timelines, and a more accurate assessment of global demand.

Genzyme also said that it has made progress in increasing the productivity of the manufacturing process for Fabrazyme. The first run of a new working cell bank (WCB) resulted in a 30% increase in productivity, and a second run is underway. Genzyme’s goal is to increase productivity an additional 30%.

Genzyme estimates that it will need to continue the 30% shipping allocation through the third quarter. The company will provide a more precise update once additional information is available about the productivity of the new WCB, the timing of regulatory clearance of the new WCB, the impact of the pending consent decree on product-release timelines, and whether Genzyme is able to finish the small amount of work-in-process Fabrazyme material that was unfinished when the interruption occurred at the Allston plant.

Manufacturing expansion update
Genzyme says it will continue to work with minimal levels of inventory for Cerezyme and Fabrazyme until the company’s new Framingham, Massachusetts, manufacturing facility is approved, which is anticipated to take place in late 2011. The new Framingham plant is mechanically complete. Preoperational activities, including cell culture, media preparation, bioreactor validation, and staff training, are currently taking place. Engineering and process validation runs are planned for this year. At its Geel, Belgium facility, Genzyme is adding a third bioreactor for the production of Myozyme, and approval is anticipated in mid-2011. The company is also working to transition fill–finish operations out of its Allston facility to its Waterford, Ireland, plant and to a contract manufacturer.

Genzyme also reported that is it seeking to add another member to its board of expertise with manufacturing expertise. Genzyme recently created the position of chief operating officer to establish a sharper focus on commercial execution and appointed executive vice-president David Meeker to this role.

See related story, FDA To Take Enforcement Action Against Genzyme for GMP Violations

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content
Advertisement
medicine factory scientist worker work in Laboratory Plants Process. medical doctor working research in pharmaceutical industry. | Image Credit: ©Quality Stock Arts – stock.adobe.com
July 25th 2025

Interfering with Interventions in Aseptic Processing

James Agalloco
Addressing human interventions to reduce their impact on contamination requires addressing broader considerations than limiting operator activities. Equipment, automation, procedural and component changes can be utilized to make the aseptic activities safer. This article offers suggestions for reducing the adverse impact of intervention throughout the aseptic process.
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
June 25th 2024

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.
Oil painting of maze with figure finding way through. Perseverance, problem-solving. Birds fly above labyrinth at sunset. Concept of challenges, resilience, journey, overcoming obstacles in business | Image Credit © Vadym - stock.adobe.com
July 25th 2025

CMC and Analytical Gaps in CRLs: Why They Persist Despite FDA Guidance and How You Can Position Yourself for Success

Christopher Cole
Many companies face FDA complete response letters due to ongoing chemistry, manufacturing, and controls, or CMC, and analytical issues despite early regulatory guidance. Review key risk points in analytical and tech transfer to better ensure commercial readiness.
Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail
May 28th 2024

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.
Mercury. Element 80 of the periodic table of chemical elements. | Image Credit: © N. Elkha - stock.adobe.com
July 24th 2025

Opposing Reactions as RFK Jr. Removes Thimerosal from Flu Vaccines

Patrick Lavery
Following an overhaul at ACIP, the HHS secretary took the advice of the committee’s new members, saying he was acting on guidance that dated back to 1999.
Question mark background | Image Credit: © Leigh-Prather - © Leigh Prather - stock.adobe.com
July 23rd 2025

ICH Q12 and Post-Approval Changes–Less than Satisfactory State of Affairs

Siegfried Schmitt
Speedier implementation of the Post-Approval Change Management Protocol is essential for it to have a positive effect on supply security, says Siegfried Schmitt, PhD, vice president, Technical at Parexel.
Related Content
Advertisement
medicine factory scientist worker work in Laboratory Plants Process. medical doctor working research in pharmaceutical industry. | Image Credit: ©Quality Stock Arts – stock.adobe.com
July 25th 2025

Interfering with Interventions in Aseptic Processing

James Agalloco
Addressing human interventions to reduce their impact on contamination requires addressing broader considerations than limiting operator activities. Equipment, automation, procedural and component changes can be utilized to make the aseptic activities safer. This article offers suggestions for reducing the adverse impact of intervention throughout the aseptic process.
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
June 25th 2024

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.
Oil painting of maze with figure finding way through. Perseverance, problem-solving. Birds fly above labyrinth at sunset. Concept of challenges, resilience, journey, overcoming obstacles in business | Image Credit © Vadym - stock.adobe.com
July 25th 2025

CMC and Analytical Gaps in CRLs: Why They Persist Despite FDA Guidance and How You Can Position Yourself for Success

Christopher Cole
Many companies face FDA complete response letters due to ongoing chemistry, manufacturing, and controls, or CMC, and analytical issues despite early regulatory guidance. Review key risk points in analytical and tech transfer to better ensure commercial readiness.
Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail
May 28th 2024

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.
Mercury. Element 80 of the periodic table of chemical elements. | Image Credit: © N. Elkha - stock.adobe.com
July 24th 2025

Opposing Reactions as RFK Jr. Removes Thimerosal from Flu Vaccines

Patrick Lavery
Following an overhaul at ACIP, the HHS secretary took the advice of the committee’s new members, saying he was acting on guidance that dated back to 1999.
Question mark background | Image Credit: © Leigh-Prather - © Leigh Prather - stock.adobe.com
July 23rd 2025

ICH Q12 and Post-Approval Changes–Less than Satisfactory State of Affairs

Siegfried Schmitt
Speedier implementation of the Post-Approval Change Management Protocol is essential for it to have a positive effect on supply security, says Siegfried Schmitt, PhD, vice president, Technical at Parexel.
About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.